| Mack MJ, et al.
|
Randomized Multicenter trial (PARTNER 1A) |
USA, Canada, Germany |
2007–2009 |
348 |
0.6% during the first year; 2% at 5 years follow-up |
| Leon MB et al.
|
Randomized Multicenter trial (PARTNER 1B) |
USA, Canada, Germany |
2007–2009 |
179 |
1.1% during the first year |
| Gleason TG, et al.
|
Randomized Multicenter trial (PIVOTAL) |
USA |
2011–2012 |
391 |
0.6% during the first year; 1.8% at 5 years follow-up |
| Regueiro A, et al.
|
Multicenter Register |
North America, South America, Europe |
2005–2015 |
20,006 |
1.1% per person-year |
| Amat-Santos IJ, et al.
|
Multicenter Registry |
North America, South America, Europe |
2007–2014 |
7,944 |
0.5% during the first year |
| Meredith IT, et al.
|
Prospective trial (REPRISE II) |
Australia and Europe |
2014–2015 |
120 |
0.8% during the first year |
| Bjursten H, et al.
|
Multicenter Registry |
Sweden |
2008–2018 |
4,336 |
1.4% during the first year |
| Moriyama N, et al.
|
Multicenter Registry |
Finland |
2008–2017 |
2,130 |
0.7% |
| Gilard M, et al.
|
Multicenter Registry |
France |
2010–2012 |
4,201 |
0.8% |
| Stortecky S, et al.
|
Multicenter Registry |
Switzerland |
2011–2018 |
7,203 |
1.29% during the first year (1.48% per person-year at first year, 0.4% per person-year after the first year) |
| Mangner N, et al.
|
Single center |
Germany |
2006–2014 |
1,820 |
2.25% during the first year, 1.82% per patient-year |
| Olsen NT, et al.
|
Single center |
Denmark |
2007–2014 |
509 |
3.1% during the first year, 2.1% per patient-year |
